-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2024.
- Lineage Cell Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$3.27M, a 31.5% increase year-over-year.
- Lineage Cell Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$18.6M, a 13.4% increase year-over-year.
- Lineage Cell Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$18.6M, a 13.4% increase from 2023.
- Lineage Cell Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$21.5M, a 18.2% increase from 2022.
- Lineage Cell Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$26.3M, a 38.9% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)